

William E Boden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1026983/publications.pdf>

Version: 2024-02-01

102
papers

11,387
citations

201575

27
h-index

39638

94
g-index

105
all docs

105
docs citations

105
times ranked

10102
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimal Medical Therapy with or without PCI for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2007, 356, 1503-1516.	13.9	4,022
2	Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. <i>New England Journal of Medicine</i> , 2011, 365, 2255-2267.	13.9	2,523
3	Initial Invasive or Conservative Strategy for Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1395-1407.	13.9	1,508
4	Management of Coronary Disease in Patients with Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1608-1618.	13.9	310
5	Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1408-1419.	13.9	287
6	Percutaneous Coronary Intervention Outcomes in Patients With Stable Obstructive Coronary Artery Disease and Myocardial Ischemia. <i>JAMA Internal Medicine</i> , 2014, 174, 232.	2.6	245
7	Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart Disease. <i>New England Journal of Medicine</i> , 2015, 373, 1937-1946.	13.9	225
8	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. <i>American Heart Journal</i> , 2018, 201, 124-135.	1.2	202
9	Relationship of Lipoproteins to Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1580-1584.	1.2	156
10	Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. <i>Journal of the American College of Cardiology</i> , 2018, 72, 330-343.	1.2	152
11	Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. <i>Nature Genetics</i> , 2019, 51, 1574-1579.	9.4	152
12	Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2021, 38, 100997.	3.2	121
13	Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: a Review. <i>Kidney International</i> , 2017, 91, 797-807.	2.6	102
14	Intensive Multifactorial Intervention for Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1348-1358.	1.2	96
15	β-Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 872-881.	0.9	84
16	Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. <i>American Heart Journal</i> , 2006, 151, 1173-1179.	1.2	82
17	The Evolving Pattern of Symptomatic Coronary Artery Disease in the United States and Canada: Baseline Characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial. <i>American Journal of Cardiology</i> , 2007, 99, 208-212.	0.7	70
18	Optimal Medical Therapy With or Without Percutaneous Coronary Intervention in Older Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1303-1308.	1.2	54

#	ARTICLE	IF	CITATIONS
19	Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. <i>European Heart Journal</i> , 2020, 41, 2304-2312.	1.0	54
20	The Therapeutic Role of Niacin in Dyslipidemia Management. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 141-158.	1.0	52
21	Medical Treatment and Revascularization Options in Patients With Type 2 Diabetes and Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 985-995.	1.2	52
22	Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2252-2266.	1.2	52
23	Physical Activity and Structured Exercise for Patients With Stable Ischemic Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 143.	3.8	48
24	Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2297-2305.	1.2	42
25	Subcutaneous Implantable Cardioverter Defibrillator for Dialysis Patients: A Strategy to Reduce Central Vein Stenoses and Infections. <i>American Journal of Kidney Diseases</i> , 2015, 66, 154-158.	2.1	33
26	Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial. <i>American Heart Journal</i> , 2016, 173, 108-117.	1.2	30
27	Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2020, 224, 65-76.	1.2	30
28	Nitrates as an Integral Part of Optimal Medical Therapy and Cardiac Rehabilitation for Stable Angina: Review of Current Concepts and Therapeutics. <i>Clinical Cardiology</i> , 2012, 35, 263-271.	0.7	28
29	Role of short-acting nitroglycerin in the management of ischemic heart disease. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4793.	2.0	28
30	HDL Hypothesis: Where Do We Stand Now?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 398.	2.0	24
31	External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. <i>Atherosclerosis</i> , 2018, 272, 80-86.	0.4	24
32	Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2049-2058.	1.2	24
33	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. <i>Circulation</i> , 2021, 144, 1380-1395.	1.6	24
34	Effect of Coronary Anatomy and Myocardial Ischemia on Long-Term Survival in Patients with Stable Ischemic Heart Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005079.	0.9	22
35	DTCA for PTCA â€” Crossing the Line in Consumer Health Education?. <i>New England Journal of Medicine</i> , 2008, 358, 2197-2200.	13.9	18
36	Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2197-2207.	1.2	18

#	ARTICLE	IF	CITATIONS
37	Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. <i>Heart</i> , 2021, 107, 1739-1747.	1.2	18
38	Mounting Evidence for Lack of PCI Benefit in Stable Ischemic Heart Disease:What More Will It Take to Turn the Tide of Treatment?. <i>Archives of Internal Medicine</i> , 2012, 172, 319.	4.3	17
39	Exercise as a Therapeutic Intervention in Patients with Stable Ischemic Heart Disease: An Underfilled Prescription. <i>American Journal of Medicine</i> , 2014, 127, 905-911.	0.6	17
40	Temporal Trends in Unstable Angina Diagnosis Codes for Outpatient Percutaneous Coronary Interventions. <i>JAMA Internal Medicine</i> , 2019, 179, 259.	2.6	17
41	Contemporary Approach to the Diagnosis and Management of Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Progress in Cardiovascular Diseases</i> , 2008, 50, 311-351.	1.6	16
42	Antianginal Therapy for Stable Ischemic Heart Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 499-510.	1.0	15
43	Death and Myocardial Infarction Following Initial Revascularization Versus Optimal Medical Therapy in Chronic Coronary Syndromes With Myocardial Ischemia: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e019114.	1.6	15
44	Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. <i>American Heart Journal</i> , 2022, 248, 72-83.	1.2	15
45	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. <i>Future Cardiology</i> , 2021, 17, 155-174.	0.5	14
46	Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial. <i>Journal of the American College of Cardiology</i> , 2022, 79, 651-661.	1.2	14
47	Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. <i>European Heart Journal</i> , 2022, 43, 148-149.	1.0	13
48	Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. <i>JAMA Network Open</i> , 2022, 5, e2148172.	2.8	11
49	Reexamining the Efficacy and Value of Percutaneous Coronary Intervention for Patients With Stable Ischemic Heart Disease. <i>JAMA Internal Medicine</i> , 2016, 176, 1190.	2.6	10
50	Impact of revascularisation on outcomes in chronic coronary syndromes: a new meta-analysis with the same old biases?. <i>European Heart Journal</i> , 2021, 42, 4652-4655.	1.0	10
51	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management. <i>JAMA Cardiology</i> , 2021, 6, 1023.	3.0	10
52	What constitutes an appropriate empirical trial of antianginal therapy in patients with stable angina before referral for revascularisation?. <i>Lancet</i> , The, 2022, 399, 691-694.	6.3	10
53	Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2013, 111, 439-444.	0.7	9
54	Is HPS2-THRIVE the death knell for niacin?. <i>Journal of Clinical Lipidology</i> , 2015, 9, 343-350.	0.6	9

#	ARTICLE	IF	CITATIONS
55	Pragmatic, adaptive clinical trials: Is 2020 the dawning of a new age?. Contemporary Clinical Trials Communications, 2020, 19, 100614.	0.5	9
56	Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial. BMJ Open, 2021, 11, e044054.	0.8	9
57	OUP accepted manuscript. European Heart Journal, 2021, , .	1.0	9
58	CABG for Complex CAD: When Will Evidence-Based Practice Align With Evidence-Based Medicine?â—. Journal of the American College of Cardiology, 2016, 67, 56-58.	1.2	8
59	Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the <scp>TRILOGY ACS</scp> Trial. Clinical Cardiology, 2016, 39, 329-337.	0.7	7
60	Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT. Journal of Clinical Lipidology, 2022, 16, 389-402.	0.6	7
61	Predictors of Initial Revascularization Versus Medical Therapy Alone in Patients With Non-â€“ST-Segmentâ€“Elevation Acute Coronary Syndrome Undergoing an Invasive Strategy. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	6
62	Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGHâ€“trial. Journal of Clinical Lipidology, 2018, 12, 741-747.e11.	0.6	6
63	Conservative versus invasive stable ischemic heart disease management strategies: what do we plan to learn from the ISCHEMIA trial?. Future Cardiology, 2016, 12, 35-44.	0.5	5
64	Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?. Circulation, 2018, 138, 858-860.	1.6	5
65	Does Physiology Trump Anatomy as the â€œBest Courseâ€“to Guide PCI Decision Making and Outcomes? â—. Journal of the American College of Cardiology, 2016, 67, 1712-1714.	1.2	4
66	Diagnostic Implications in the Aftermath of the ISCHEMIA Trial. American Journal of Cardiology, 2020, 125, 1438-1440.	0.7	4
67	Defining the Proper SYNTAX for Long-Term Benefit of Myocardial Revascularization With Optimal Medical Therapy. Journal of the American College of Cardiology, 2021, 78, 39-41.	1.2	4
68	Is there equivalence between PCI and CABG surgery in long-term survival of patients with diabetes? Importance of interpretation biases and biological plausibility. European Heart Journal, 2021, 43, 68-70.	1.0	4
69	Evaluation of the stable coronary artery disease patient: Anatomy trumps physiology. Trends in Cardiovascular Medicine, 2014, 24, 332-340.	2.3	3
70	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. Heart, 2016, 102, 1221-1229.	1.2	3
71	Health-related quality of life outcomes with prasugrel among medically managed non-â€“ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial. American Heart Journal, 2016, 178, 55-64.	1.2	3
72	Reconsidering the Gatekeeper Paradigm for Percutaneous Coronary Intervention in Stable Coronary Disease Management. American Journal of Cardiology, 2017, 120, 1450-1452.	0.7	3

#	ARTICLE	IF	CITATIONS
73	Meta-Analysis of the Effect of Percutaneous Coronary Intervention on Death and Myocardial Infarction in Patients With Stable Coronary Artery Disease and Inducible Myocardial Ischemia. <i>American Journal of Cardiology</i> , 2020, 133, 171-174.	0.7	3
74	PCSK9 Inhibition for Therapeutic Decision-Making. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2309-2311.	1.2	3
75	To stent or not to stent? Treating angina after ISCHEMIA—introduction. <i>European Heart Journal</i> , 2021, 42, 1387-1400.	1.0	3
76	To stent or not to stent? Treating angina after ISCHEMIA—why a conservative approach with optimal medical therapy is the preferred initial management strategy for chronic coronary syndromes: insights from the ISCHEMIA trial. <i>European Heart Journal</i> , 2021, 42, 1394-1400.	1.0	3
77	Translating the findings of ISCHEMIA into clinical practice: a challenging START. <i>EuroIntervention</i> , 2020, 16, e953-e956.	1.4	3
78	Optimizing Dyslipidemic Cardiovascular Residual Risk Reduction With Icosapent Ethyl in Post-MI Patients. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1672-1674.	1.2	3
79	Role of Dual Antiplatelet Therapy in Symptomatic Patients with Established Vascular Disease: Putting the CHARISMA Trial into Therapeutic Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 207-216.	1.3	2
80	Why Optimal Medical Therapy Should Be a Universal Standard of Care —. <i>Journal of the American College of Cardiology</i> , 2015, 66, 774-776.	1.2	2
81	Revascularization options in stable coronary artery disease: it is not how to revascularize, it is whether and when to revascularize. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 505-514.	0.6	2
82	Effect of Baseline Exercise Capacity on Outcomes in Patients With Stable Coronary Heart Disease (A) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	2
83	A PROMISE Fulfilled That Quality-of-Life Assessments Afford Incremental Value to Coronary Artery Disease Management. <i>Circulation</i> , 2016, 133, 1989-1991.	1.6	2
84	Role of Imaging in the Management of Stable Ischemic Heart Disease. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 335-337.	2.3	2
85	Risk Prediction Tool for Assessing the Probability of Death or Myocardial Infarction in Patients With Stable Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2020, 130, 1-6.	0.7	2
86	The nomenclature vagaries for the clinical manifestations of myocardial ischemic syndromes — A call to action. <i>International Journal of Cardiology</i> , 2020, 304, 5-7.	0.8	2
87	The Rising Urgency to Pivot Back Toward Hippocratic Medicine. <i>American Journal of Medicine</i> , 2022, 135, 49-52.	0.6	2
88	As REGARDS Treatment Goal Attainment Compared With COURAGE. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1634-1635.	1.2	1
89	A Novel Diagnostic Approach for Evaluating Suspected Coronary Artery Disease. <i>American Journal of Medicine</i> , 2016, 129, 557-559.	0.6	1
90	Role of Ranolazine in Reducing Angina, Subsequent Revascularization, and Healthcare Expenditures in Stable Ischemic Heart Disease. <i>American Journal of Cardiology</i> , 2019, 123, 1729-1731.	0.7	1

#	ARTICLE	IF	CITATIONS
91	Deferral of PCI, a safe strategy in diabetic patients with chronic coronary syndromes. <i>Heart</i> , 2020, 106, 1627-1628.	1.2	1
92	Will REFINE Resurrect the "Ischemia Hypothesis"? <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 654-656.	2.3	1
93	Interpreting the results of the COURAGE trial: a non-interventionalist perspective. <i>Reviews in Cardiovascular Medicine</i> , 2009, 10 Suppl 2, S34-44.	0.5	1
94	The continued importance of optimal medical therapy with or without revascularization in diabetic patients with coronary artery disease. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 632-634.	2.3	0
95	MY APPROACH to managing stable ischemic heart disease. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 753-754.	2.3	0
96	Should Beta-Blockers Continue to Be Used in Post-Percutaneous Coronary Intervention Patients Without Myocardial Infarction?. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1649-1651.	1.1	0
97	Successful percutaneous coronary intervention significantly improves coronary sinus blood flow as assessed by transthoracic echocardiography. <i>Journal of Echocardiography</i> , 2018, 16, 65-71.	0.4	0
98	Evolving from volume to value, or to a bolder vision of reimbursement reform?. <i>American Heart Journal</i> , 2018, 204, 174-177.	1.2	0
99	Letter by Boden Regarding Article, "Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials"; <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006632.	0.9	0
100	RESPONSE: The Exit Interview of a Professional Lifetime. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2256-2257.	1.2	0
101	The sounds of silence. <i>European Heart Journal</i> , 0, , .	1.0	0
102	Evolving Roles of Optimal Medical Therapy and PCI in Chronic Coronary Syndrome Patients with Stable Angina: Introduction. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	1.3	0